肿瘤类器官共培养在免疫治疗药物中的研究进展  

Progress of research on tumor organoid co⁃culture in immunotherapeutic drugs

作　　者：秦亚芳 贾峥[1] 张泽伦 韩璐璐 黄杰[1] QIN Yafang;JIA Zheng;ZHANG Zelun;HAN Lulu;HUANG Jie(National Institutes for Food and Drug Control,Beijing,China,100050)

机构地区：[1]中国食品药品检定研究院,北京100050

出　　处：《分子诊断与治疗杂志》2025年第1期192-196,共5页Journal of Molecular Diagnostics and Therapy

基　　金：中国工程院战略研究与咨询项目(2023XBZD11)。

摘　　要：免疫治疗药物通过调节机体的免疫系统治疗癌症,免疫系统发挥作用,往往取决于肿瘤内部复杂的免疫微环境。传统肿瘤模型难以充分模拟和展示肿瘤内部复杂的肿瘤免疫微环境,所以肿瘤个性化免疫治疗研究需要建立在肿瘤发生发展中能充分模拟免疫系统共同参与的模型。肿瘤类器官为药物筛选提供新的思路,肿瘤类器官共培养模型为研究肿瘤细胞与免疫细胞之间复杂的相互作用提供了有力的实验平台。在本篇综述中,对比了药物筛选模型,介绍了肿瘤类器官共培养模型的构建方法以及免疫治疗药物通过共培养模型在药物筛选中表现出的潜力与应用前景。Immunotherapeutic drugs treat cancer by regulating the bodys immune system,and the immune system's role often depends on the complex tumor immune microenvironment.Traditional tumor models struggle to fully simulate and demonstrate the intricate immune microenvironment within tumors,so research on personalized tumor immunotherapy must establish a model that can accurately replicate the immune system's involvement in tumor development.Tumor organoids offer new opportunities for drug screening,and tumor organoid co⁃culture models serve as a robust experimental platform for studying the complex interactions between tumor cells and immune cells.This review compares drug screening models,outlines the construction method of tumor organoid co⁃culture models,and discusses the potential and application prospects of immunotherapeutic drugs in drug screening through co⁃culture models.

关 键 词：药物筛选模型 肿瘤类器官共培养 免疫治疗药物 

分 类 号：R730.51[医药卫生—肿瘤]